Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
RetinAI logo — Improving R&D of first-in-human drug candidates in pharma. S...

RetinAI

Improving R&D of first-in-human drug candidates in pharma. Supercharging clinical trials. Elevating the quality of care.

Founded 2017 Switzerland Bern, Switzerland 43 employees Series B Total: $15.14M AI, Computing +3

General Information

Company Name RetinAI
Founded Year 2017
Location Switzerland Bern, Switzerland +2
Employees 43
Industries AI, Computing, Health Care +2
Funding Stage Series B
Social

Get notified when RetinAI moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About RetinAI

RetinAI is a Swiss & US-based software company focused on improving and supporting R&D of first-in-human drug candidates, supercharging management and oversight of clinical trials, and enabling the research needed to elevate the quality of care on patients with eye diseases. The company's slogan "Improving R&D of first-in-human drug candidates in pharma. Supercharging clinical trials. Elevating the quality of care." succinctly encapsulates its mission. Founded in 2017, RetinAI operates in the AI, Computing, Health Care, Information Technology, and Machine Learning industries, with its headquarters in Switzerland. The company's fundamental belief is that in the future, every patient will use drugs alongside a digital application that will enable them and their physicians to better assess the right drug, in the right amount and the right frequency for patients. By building tools to collect, analyze, and organize health data, RetinAI is making strides towards this goal. Notably, the company secured a Series B investment on 16 October 2024. Although the specific investors of this round are not mentioned, this latest investment signifies a significant milestone in the company's journey towards shaping the future of healthcare and pharmaceuticals.

Taxonomy: medical image analysis, med-tech, ophthalmology, optical coherence tomography, Fundus Image Photography, Retinal Angiography, age-related macular degeneration, diabetic retinopathy, glaucoma, Multiple Sclerosis, alzheimer, parkinson, digital health

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 4
Investor
•••• •••• 		16 Oct 2024
Series A •••••• 5
Investor Investor Investor
•••• •••• 		02 May 2024
Seed Round •••••• 2
Investor Investor
11 Jun 2019
Grant •••••• 1 •••• •••• 19 Mar 2019
Seed Round •••••• 1
Investor
15 Dec 2017

View All 8 Funding Rounds

RetinAI Alternatives & Competitors

RetinAI vs
Gentris | A CGI Company
Gentris | A CGI Company United States

Gentris, a subsidiary of Cancer Genetics, Inc., is a global provider of pharmacogenomic testing and...

Series Unknown
4 employees
Biotechnology
Compare RetinAI vs Gentris | A CGI Company
RetinAI vs
Alumis
Alumis United States

Transforming the lives of patients living with immune-mediated diseases using a precision approach.

Series C
249 employees
Biotechnology, Health Care
Compare RetinAI vs Alumis
RetinAI vs
GenenDesign Co., Ltd
GenenDesign Co., Ltd China

WHO WE ARE GenenDesign was founded in 2007 with the dedication to build the largest cancer model pl...

1 employees
Biotechnology, Health Care
Also compare with: RetinAI vs Pinscriptive, Inc. Pinscriptive, Inc.

FAQ About RetinAI

Improving R&D of first-in-human drug candidates in pharma. Supercharging clinical trials. Elevating the quality of care.
RetinAI was founded in 2017.
RetinAI is headquartered in Bern, Switzerland.
RetinAI operates in the following industries: AI, Computing, Health Care, Information Technology, Machine Learning.
RetinAI has approximately 43 employees.
RetinAI has completed 8 funding rounds, raising a total of $15.14M. The latest funding stage is Series B.
Top alternatives and competitors to RetinAI include Gentris | A CGI Company, Alumis, GenenDesign Co., Ltd, Cancer Therapy Advisor, Pinscriptive, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
RetinAI and Gentris | A CGI Company are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors RetinAI and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy